Parse Biosciences Expands Global Reach with the South Australian Genomics Centre as Certified Service Provider
Parse Biosciences, the leader in scalable and accessible single cell sequencing, is pleased to welcome the South Australian Genomics Centre (SAGC) as the newest member of its Certified Service Provider (CSP) Program. As a certified provider, the SAGC expands access to Parse’s pioneering single cell technology, equipping researchers across Australia and the broader Asia-Pacific region with the tools and expertise to accelerate discovery at scale.
Introduced in 2024, Parse’s CSP Program was created to connect researchers with trusted service providers for outsourcing single cell projects, ranging from small-scale exploratory studies to high-throughput, routine analyses. By maintaining rigorous standards, the program ensures providers deliver high-quality, scalable solutions that drive scientific discovery forward.
“We are thrilled to be the first Genomics Centre in Australasia to partner with Parse Biosciences as a Certified Service Provider. Their single cell technology has quickly gained traction amongst the Australian research community due to its scalability, sample fixation and cost-effectiveness,” said Dr. Sen Wang, SAGC Centre Manager.
"Expanding our Certified Service Provider Program is key to ensuring researchers have reliable access to high-quality single cell sequencing solutions," said Alex Rosenberg, CEO and co-founder of Parse Biosciences. "With the SAGC joining the program, scientists now have another trusted partner equipped to support projects of all sizes with the scalability and precision they need to drive discovery."
About the South Australian Genomics Centre (SAGC)
The SAGC is located in Adelaide, South Australia with labs in both the South Australian Health and Medical Research Institute (SAHMRI) and Flinders University. The SAGC is NATA accredited and offers a wide range of genomics and bioinformatics services (e.g., RNA, WGS, WES, epigenomics, metagenomics, single cell and spatial). The SAGC supports all areas of genomics (animal, plant, environmental, microbial, and human) and clients from academia, healthcare and industry.
For more information, please visit https://sa-genomics.com.au/
About Parse Biosciences
Parse Biosciences is a global life sciences company dedicated to accelerating advancements in human health and scientific research. By empowering researchers to conduct single cell sequencing with unparalleled scale and simplicity, Parse’s innovative solutions are driving breakthroughs in cancer treatment, tissue repair, stem cell therapy, and more.
Built upon transformative technology developed at the University of Washington, Parse Biosciences has raised over $100 million and is used by over 2,500 labs worldwide. Its expanding product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and Trailmaker for advanced data analysis.
Headquartered in Seattle’s vibrant South Lake Union district, Parse Biosciences recently inaugurated a 34,000-square-foot facility featuring state-of-the-art laboratories to support its mission of advancing global research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320291525/en/
Contacts
Kaitie Kramer
kkramer@parsebiosciences.com | 858.504.0455
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AlbaCore Launches its Senior Direct Lending Strategy, with Commitments from ADIA and Mitsubishi UFJ Trust and Banking Corporation27.3.2025 08:00:00 CET | Press Release
European credit specialist AlbaCore Capital Group (“AlbaCore”) today announces the launch of a new Senior Direct Lending Strategy (“the Strategy”), having secured anchor investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and Mitsubishi UFJ Trust and Banking Corporation (the “Trust Bank”). AlbaCore has successfully completed its first close, bringing together an expected $1.8 billion in investable capital. With the launch of the Strategy, AlbaCore is well positioned to take advantage of the growing opportunity set to finance loans, further expanding its market presence and delivering enhanced value to clients globally. “Securing commitments from ADIA and the Trust Bank for the first vintage of our Senior Direct Lending Strategy is a testament to the attractiveness of the opportunity set in the market and how well positioned AlbaCore is to take advantage of it,” said David Allen, Managing Partner and Chief Investment Officer at AlbaCore. The Strateg
Nederlandse Innovatie Maatschappij (NIM) Leads H2ESTIA Project: The Future of Emission-Free Cargo Transport27.3.2025 07:00:00 CET | Press Release
The maritime industry is taking a large step toward sustainability with the launch of the H2ESTIA Project, a groundbreaking initiative to develop the world’s first zero-emission general cargo ship powered by liquid hydrogen. Led by the Dutch Innovation Company (NIM – www.nim-bv.nl ) and supported by the Dutch Ministry of Infrastructure and Water Management, this initiative is a key pillar of the Maritime Masterplan, setting a new standard for decarbonizing European maritime logistics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326530510/en/ Concept design of the zero-emission hydrogen powered bulk carrier The project focuses on designing, constructing, and demonstrating a hydrogen-powered cargo vessel that will operate in the North Sea and beyond. Managed by Van Dam Shipping, the ship is designed to transport bulk goods, eliminating harmful emissions and redefining the future of sustainable shipping. At the heart of t
IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale27.3.2025 07:00:00 CET | Press Release
IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production will use IFF’s Designed Enzymatic Biomaterial™ (DEB) platform technology, integrated at the IFF biorefinery in Kotka, Finland. "Our partnership with Kemira has reached a significant milestone, enabling us to scale the production of groundbreaking biobased materials to meet the large and growing demand for high-performing and sustainable alternatives to fossil-derived polymers," said Erik Fyrwald, IFF CEO. "IFF’s DEB technology not only guarantees superior purity and consistency compared to traditional biopolymers but also en
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis27.3.2025 07:00:00 CET | Press Release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health Canada to launch the Phase 2a INFLAM MOTION “Proof-of-Concept” study for 4P004 in patients with knee osteoarthritis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326675460/en/ Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Canada. It will enroll 129 patients to evaluate, for the first time, the efficacy of 4P004 in individuals with knee osteoarthritis. 4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti
Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-0127.3.2025 07:00:00 CET | Press Release
Curatis Holding AG (SIX:CURN, ‘Curatis’) reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution business by 30% per cent to CHF 9.5m in the full year 2024 compared to 2023. Further key statements: Curatis is increasing the estimate for the number of patients addressed in the lead project C-PTBE-01 by a factor of 20. The reason for this is that Curatis can apply for a biologics licence for C-PTBE-01, which grants 12 years of market protection in the USA. This suggests an expansion of the indications, namely from PTBE in diffuse midline glioma (DMG) in children to PTBE in other primary and metastatic brain tumours in children and adults. A meeting with the US Food and Drug Administration (FDA) to discuss a potential pivotal Phase III trial for C-PTBE-01 is in preparation and is targeted for Q2. The strong cash position of CHF 3m at the end of the year combined with the positive, growing c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom